Humacyte, Inc. Stock Analysis & AI Score
Humacyte, Inc. (HUMA) has an ST Score of 33.8 (C-), driven by its Forecast (A) and held back by its Momentum (D-). Analysts rate it Buy with a $2.00 price target (+251.7% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Humacyte, Inc. (HUMA) has an ST Score of 33.8 (C-), driven by its Forecast (A) and held back by its Momentum (D-). Analysts rate it Buy with a $2.00 price target (+251.7% upside).
- Strongest
- ForecastA
- Weakest
- MomentumD-
All factor grades
- ForecastA
- GrowthB
- Financial StrengthC-
- ValuationD-
- ProfitabilityD-
- MomentumD-
- Piotroski3/9
Contact
HUMA stock: frequently asked questions
What is HUMA's ST Score?
Humacyte, Inc. (HUMA) has an ST Score of 33.8 (C-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is HUMA a buy, hold, or sell?
Analysts rate HUMA a Buy, with a price target of $2.00 (+251.7% vs the current price). Our ST Score grades it C- (33.8/100). The ST Score is a data-driven signal, not a recommendation.
What are HUMA's factor grades?
Valuation D-, Profitability D-, Financial Strength C-, Momentum D-, Growth B, Forecast A.
What is HUMA's valuation grade?
Humacyte, Inc. (HUMA) earns a valuation grade of D-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is HUMA's growth grade?
Humacyte, Inc. (HUMA) earns a growth grade of B, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is HUMA's profitability grade?
Humacyte, Inc. (HUMA) earns a profitability grade of D-, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is HUMA's financial strength grade?
Humacyte, Inc. (HUMA) earns a financial strength grade of C-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for HUMA?
The average analyst price target for Humacyte, Inc. (HUMA) is $2.00 from 11 analysts, which is +251.7% versus the recent price of $0.57.
What is HUMA's Piotroski score?
Humacyte, Inc. (HUMA) has a Piotroski F-Score of 3 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.